Ke XY - Search Results

1

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.

Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ. Shi YK, et al. Among authors: ke xy. Anticancer Drugs. 2013 Jul;24(6):641-7. doi: 10.1097/CAD.0b013e3283610b5d. Anticancer Drugs. 2013. PMID: 23571496 Clinical Trial.

2

[Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].

Lu DP, Liu KY, Guo NL, Shi YK, He XH, Lou FD, Da WM, Zhang BL, Wang LX, Ke XY. Lu DP, et al. Among authors: ke xy. Zhonghua Xue Ye Xue Za Zhi. 2003 Feb;24(2):68-70. Zhonghua Xue Ye Xue Za Zhi. 2003. PMID: 12697098 Clinical Trial. Chinese.

3

[Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].

Weng Y, Gao ZF, Liu K, Zhang WJ, Ke XY, Li M. Weng Y, et al. Among authors: ke xy. Zhonghua Nei Ke Za Zhi. 2005 Sep;44(9):681-3. Zhonghua Nei Ke Za Zhi. 2005. PMID: 16202261 Chinese.

4

[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].

Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL. Lin TY, et al. Among authors: ke xy. Ai Zheng. 2005 Dec;24(12):1421-6. Ai Zheng. 2005. PMID: 16351785 Clinical Trial. Chinese.

5

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY. Shi YK, et al. Among authors: ke xy. Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9. Zhonghua Yi Xue Za Zhi. 2006. PMID: 17313855 Clinical Trial. Chinese.

6

Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.

Zhou DB, Yu L, Du X, Jin J, Cai Z, Chen F, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, DeMarco D, Chen N, Mei J, Wang J, Hou J. Zhou DB, et al. Int J Hematol. 2015 Jun;101(6):569-77. doi: 10.1007/s12185-015-1771-7. Epub 2015 Mar 10. Int J Hematol. 2015. PMID: 25753225 Clinical Trial.

7

Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.

Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, Hu J, Hu Y, Ke X, Li J, Liang Y, Liu T, Lv Y, Ren H, Sun A, Wang J, Zhao C, Salman M, Sun S, Howes A, Wang J, Wu P, Li J. Huang X, et al. Cancer Med. 2018 Apr;7(4):1043-1055. doi: 10.1002/cam4.1337. Epub 2018 Mar 13. Cancer Med. 2018. PMID: 29533000 Free PMC article. Clinical Trial.

8

PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.

Zheng W, Gao Y, Ke X, Zhang W, Su L, Ren H, Lin N, Xie Y, Tu M, Liu W, Ping L, Ying Z, Zhang C, Deng L, Wang X, Song Y, Zhu J. Zheng W, et al. BMC Cancer. 2018 Sep 21;18(1):910. doi: 10.1186/s12885-018-4782-y. BMC Cancer. 2018. PMID: 30241515 Free PMC article. Clinical Trial.

9

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.

10

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.

Hong X, Song Y, Huang H, Bai B, Zhang H, Ke X, Shi Y, Zhu J, Lu G, Liebscher S, Cai C. Hong X, et al. Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y. Target Oncol. 2019. PMID: 30904980 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

237 results

Search Page